Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain⦠read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
$0.34
Price+2.81%
$0.01
$7.510m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$560
-
1y CAGR-
3y CAGR-
5y CAGR-$8.450m
-
1y CAGR-
3y CAGR-
5y CAGR-$1.01
-
1y CAGR-
3y CAGR-
5y CAGR$5.591m
$6.802m
Assets$1.211m
Liabilities-
Debt0.00%
-
Debt to EBITDA-$6.483m
-
1y CAGR-
3y CAGR-
5y CAGR